History
Documents created during the development process.
Assessment report sent for information
Background information
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix A -matrix of stakeholders
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appendix B -GE Proposal Paper May 2015
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: equality impact assessment - guidance development
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: equality impact assessment - guidance development
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination document
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: consultee and commentator comments on the ACD
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis comments
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Cystic Fibrosis Trust comments
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Chartered Society of Physiotherapy comments
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Nursing comments
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Paediatrics and Child Health comments
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Healthcare Improvement Scotland comments
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Expert comments on the ACD
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Professor Andrew Greening (clinical specialist) nominated by Healthcare Improvement Scotland
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Dr Robert Ian Ketchell (clinical specialist) nominated by Forest Laboratories UK
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Emma Lake and Nikki Samsa (patient experts) nominated by the Cystic Fibrosis Trust - joint submission
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Comments on the ACD received from the public through the NICE website
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Comments on the ACD Received from the Public through the NICE Website
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Additional public comment received via email (reference article not included)
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: additional evidence
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Updated Patient Access Scheme (PAS) submission from Forest Laboratories UK
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Economic analysis of updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR)
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Summary of non-inferiority analysis in updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR)
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appraisal consultation
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: appraisal consultation
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: evaluation report
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: overview
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: assessment report addendum - Novartis PAS analysis
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: consultee and commentator comments on the assessment report
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Forest Laboratories UK
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: British Thoracic Society (endorsed by Royal College of Physicians)
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Chartered Society of Physiotherapy
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Paediatrics and Child Health
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Healthcare Improvement Scotland
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee and commentator comments on the assessment report
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: manufacturer submissions (executive summary only)
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Forest Laboratories UK Executive Summary
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis Executive Summary
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis PAS submission
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: non-manufacturer submission
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: British Thoracic Society (endorsed by Royal College of Physicians)
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Nursing
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Royal College of Paediatricians and Child Health
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: expert written personal statements
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Greening
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Ketchell
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Lake
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Samsa
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: additional information - personal perspectives from experts who could not attend the first committee meeting on the rescheduled date
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Hull
-
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Morton
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin [ID342]: assessment report
-
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin [ID342]: assessment report
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: scoping Equality Impact Assessment form
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: scoping Equality Impact Assessment form
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final protocol
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final protocol
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final scope
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final scope
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final matrix
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: final matrix
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on draft scope
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on draft scope
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on provisional matrix
-
Cystic fibrosis (pseudomonas lung infection) colistimethate powder and tobramycin powder: response to consultee and commentator comments on provisional matrix
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation October 2010
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation October 2010
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix for consultation October 2010
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix for consultation October 2010
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation (pre-referral)
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: draft scope for consultation (pre-referral)
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix (pre-referral)
-
Cystic fibrosis (Pseudomonas aeruginosa lung infection) - colistimethate sodium: provisional matrix (pre-referral)
-